Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

BioMark Diagnostics Inc C.BUX

Alternate Symbol(s):  BMKDF

BioMark Diagnostics Inc. is a liquid biopsy company. The Company is developing a molecular diagnostics technology platform, which leverages the power of metabolomics and machine learning algorithms to bring new cancer diagnostics to market and improve cancer prognosis by allowing physicians to detect carcinomas in the pre-symptomatic stages. The technology can also be used for measuring response to treatment and potentially for serial monitoring of cancer survivors. Its cancer diagnostics technology platform leverages Omics and machine learning with a focus on cancers that are hard to detect and treat cancers. Its liquid biopsy assay detects Spermidine/spermine N-acetyltransferase 1 (SSAT1). SSAT1 is an enzyme with elevated levels in numerous cancers. Its oncology has developed a new high powered liquid biopsy metabolic panel assay. The new metabolic assay is instrumental for early-stage diagnosis of lung cancer. The liquid biopsy metabolic panel has demonstrated clinical detections.


CSE:BUX - Post by User

BioMark Diagnostics Inc
Bullboard Posts
User Avatar Image
(0)
•••
Post by soduhpopon Feb 06, 2017 1:20pm
176 Views
Post# 25805294

global cancer diagnostics - BUX is named key player

global cancer diagnostics - BUX is named key player This area is heating up and will greatly disrupt the market in a positive way for people and BUX.

Key Players:
The major participants of this market are: Cancer Diagnostics, Inc. (US), Myriad Genetics (Switzerland), Cancer Genetics Inc. (US), Inspirata (US), Genomic Health, Inc. (US), Paradigm Diagnostics, Inc.(US), MEDITE Cancer Diagnostics, Inc. (US), MDxHealth (US), Biotheranostics (US), Pacific Edge (New Zealand), Ventana Medical Systems, Inc., BioMark Diagnostics Inc. (Canada), 20/20 GeneSystems Inc. (US), Provista Diagnostics, Inc. (US), Armune BioScience (US), Arquer Diagnostics Ltd, Oncimmune Limited (UK), MetaCell (Czech Republic).


https://www.satprnews.com/2017/01/06/global-cancer-diagnostics-market-expected-to-grow-at-cagr-12-from-2016-to-2022/

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities